Long lasting clinical response to chemotherapy for advanced uterine leiomyosarcoma: a case report

Journal of Medical Case Reports

Alberto Ravaioli²  Antonio Polselli³  Carlotta Santelmo¹  Eleonora Barzotti¹  Fabrizio Drudi¹  Giuseppe Pasini¹  Claudio Ridolfi³ 

[1] Oncology Department, ‘Infermi’ Hospital, Via Settembrini 2, Rimini, 47923, Italy;IRST (The Cancer Institute of Romagna), Via Piero Maroncelli 40, Meldola, FC 47014, Italy;Oncology Department, ‘Cervesi’ Hospital, Via Ludwig Van Beethoven 1, Cattolica, RN 47841, Italy

关键词: Response;    Chemotherapy;    Advanced leiomyosarcoma;   

Others  :  1195105
DOI  :  10.1186/1752-1947-7-29

 received in 2012-10-25, accepted in 2012-12-19,  发布年份 2013

【 摘 要 】

Introduction

Uterine leiomyosarcoma is one of the most frequent uterine sarcomas. In the metastatic setting it is sensitive to doxorubicin, ifosfamide, gemcitabine, docetaxel and a few other drugs, but time to progression is generally short. For this reason prognosis is often poor and there are few reports in the literature of long responders.

Case presentation

We report a case of a 40-year-old Caucasian woman with metastatic uterine leiomyosarcoma who began treatment six years before the presentation of this case report and for the following six years underwent ten lines of chemotherapy, achieving excellent results and a good quality of life. Among the treatments administered we observed a long response to temolozomide, an unconventional drug for this kind of disease.

Conclusion

Although there are few chemotherapeutic options for the management of metastatic uterine leiomyosarcoma, a small number of patients have an unexpected long lasting response to treatment. For this reason further research is needed to identify new therapeutic agents and the predictive factors for the achievement of response.

【 授权许可】

   
2013 Ridolfi et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Seddon BM, Davda R: Uterine sarcomas–Recent progress and future challenges. Eur J Radiol 2011, 78:30-40.
• [2]Abd-Alla HM, El-Sebaie MM, Ali NM: Uterine sarcoma: analysis of treatment failure and survival. J Egypt Natl Canc Inst 2000, 12:245-251.
• [3]D'Angelo E, Prat J: Uterine sarcomas: a review. Gynecol Oncol 2010, 116:131-139.
• [4]Kanjeekal S, Chambers A, Fung MF, Verma S: Systemic therapy for advanced uterine sarcoma: a systematic review of the literature. Gynecol Oncol 2005, 97:624-637.
• [5]Hensley ML: Role of chemotherapy and biomolecular therapy in the treatment of uterine sarcomas. Best Pract Res Clin Obstet Gynaecol 2011, 25:773-782.
• [6]Aksoy S, Hizli D, Sarici S, Öcalan R, Köse MF, Güler N: A retrospective review of metastatic or recurrent uterine sarcomas treated with ifosfamide and doxorubicin (IMA). UHOD 2008, 18:129-134.
• [7]van der Graaf WT, Blay JY, Chawla SP, Kim DW, Bui-Nguyen B, Casali PG, Schöffski P, Aglietta M, Staddon AP, Beppu Y, Le Cesne A, Gelderblom H, Judson IR, Araki N, Ouali M, Marreaud S, Hodge R, Dewji MR, Coens C, Demetri GD, Fletcher CD, Dei Tos AP, Hohenberger P, EORTC Soft Tissue and Bone Sarcoma Group, PALETTE study group: Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2012, 379:1879-1886.
• [8]Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, Kros JM, Hainfellner JA, Mason W, Mariani L, Bromberg JE, Hau P, Mirimanoff RO, Cairncross JG, Janzer RC, Stupp R: MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005, 352:997-1003.
• [9]Penel N, Van Glabbeke M, Marreaud S, Ouali M, Blay JY, Hohenberger P: Testing new regimens in patients with advanced soft tissue sarcoma: analysis of publications from the last 10 years. Ann Oncol 2011, 22:1266-1272.
• [10]Woll PJ, Judson I, Lee SM, Rodenhuis S, Nielsen OS, Buesa JM, Lorigan PC, Leyvraz S, Hermans C, van Glabbeke M, Verweij J: Temozolomide in adult patients with advanced soft tissue sarcoma: a phase II study of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 1999, 35:410-412.
• [11]Talbot SM, Keohan ML, Hesdorffer M, Orrico R, Bagiella E, Troxel AB, Taub RN: A phase II trial of temozolomide in patients with unresectable or metastatic soft tissue sarcoma. Cancer 2003, 98:1942-1946.
• [12]Trent JC, Beach J, Burgess MA, Papadopolous N, Chen LL, Benjamin RS, Patel SR: A two-arm phase II study of temozolomide in patients with advanced gastrointestinal stromal tumors and other soft tissue sarcomas. Cancer 2003, 98:2693-2699.
• [13]Garcia del Muro X, Lopez-Pousa A, Martin J, Buesa JM, Martinez-Trufero J, Casado A, Poveda A, Cruz J, Bover I, Maurel J, Spanish Group for Research on Sarcomas: A phase II trial of temozolomide as a 6-week, continuous, oral schedule in patients with advanced soft tissue sarcoma: a study by the Spanish Group for Research on Sarcomas. Cancer 2005, 104:1706-1712.
• [14]Anderson S, Aghajanian C: Temozolomide in uterine leiomyosarcomas. Gynecol Oncol 2005, 98:99-103.